This new accolade joins our previous recognitions: - 🏆 2021: Prix de la Région Pays de la Loire at Start West. - 🏆 2022: Award for job creation at Startups & Innovation Day Each award reminds us of all the progress we've made since our launch in 2021.

Last week, our CEO Frédéric Pette proudly received a trophy from @bpifrance, marking BioMAdvanced Diagnostics' selection to join the prestigious Club Excellence. #Atlanpole #AtlanpoleBiotherapies #LaFrenchCare #medtech

🚀 [Q1 2024 – recap] Our first 3 months of 2024 have already been marked by several key milestones, enabling us to stay confident about our current scheduled roadmap and to prepare for a global launch. Details : biomadvanced-diagnostics.com… #MedTech #LaFrenchCare

Why can we reach the market faster than most biotech companies and other medtech ? 1️⃣ THE ABILITY TO ADOPT AN AGILE DEVELOPMENT PROCESS 2️⃣ A MORE STREAMLINED REGULATORY APPROVAL PROCESS 3️⃣ THE USE OF BIO-COLLECTIONS biomadvanced-diagnostics.com… #nantes #medtech

Wondering how we're able to process our clinical trials at such a rapid pace? The secret lies in Bio-collections (or Biobanks). These collections of samples (blood, biopsies, etc.) and clinical data, gathered from patients recruited without bias. #MedTech

“BioMAdvanced Diagnostics” and its logo have been successfully registered as Trademarks in the United States of America. Another step in our journey towards delivering great diagnostics solutions to transplanted patients and their clinicians around the world! #medtech #nantes

Why does this matter ? Companies involved in the development and manufacturing of Medical Devices are REQUIRED to have a Certified Quality System in accordance with the ISO 13485 standard.

[Milestone] BiomAdvanced Diagnostics is ISO 13485 certified by BSI under certificate number MD 775018. #ISO13485 #RegulatoryAffairs #MedTech

These tests were conducted independently on two separate days under the supervision of our team. ▶▶▶We are pleased to announce that the product has met all of our expectations. (5/5)

📌In pursuit of this objective, two Medical Biology Engineers from a leading French University Hospital biology lab visited our own molecular biology lab. Without prior knowledge of the product, they conducted tests solely relying on the provided instructions for use. (4/5)

This phase is aiming at verifying/validating the user interfaces while taking into account the human factor (essentially checking the ease of use and the safety/risk management). (3/5)

As our product development progresses, we are currently immersed in the summative usability assessment of our kidney IVD test, encompassing both the kit and software components. (2/5)

Crucial to our product : its ease of use and its safety. How do we ensure it ? By conducting specific usability testing (1/5)

We reflected on the massive achievements of 2023 and the upcoming year. Two major challenges ahead of us : ✔Kidney product : prospective European multicentric study, last step before CE marking by the end of 2025. ✔Lung product : analytical validation #medtech #IVD #Nantes

Despite our global ambition, we do not forget our french roots ! We organized this week a friendly gathering that brought together our cofounders and our entire operational team around a Galette des Rois (King Cake).

Financial Boost: Bpifrance's €250K Seed Investment propels us forward, optimizing cash flow for a targeted Series A capital increase in H1 2024. biomadvanced-diagnostics.com… #MedTech #LaFrenchTech #Startup

🚀 Exciting News: Bpifrance just granted us a strategic €250K Seed Investment, fueling our financial strength. This positions us for a crucial Series A capital increase in H1 2024. 💼 biomadvanced-diagnostics.com… #MedTech #LaFrenchTech #Startup

BioMAdvanced Diagnostics secures an exclusive license with SATT @OuestValo 👩‍⚕️ Meet the Inventors! 🌟 Co-founders Dr. Sophie Brouard and Dr. Richard Danger are amongst the brilliant minds behind this latest patent. #Nantes #LaFrenchCare #MedTech #FrenchTech #Lungtransplant

SATT Ouest Valorisation manages the IP of this patent ("A blood gene score to prognose chronic lung allograft dysfunction.") on behalf of INSERM, @Nantes Université and the CHU de Nantes. #Nantes #LaFrenchCare #MedTech #FrenchTech #IntellectualProperty #IP

2️⃣The selection process was extremely rigourous. BioMAdvanced Diagnostics was chosen to represent the Pays de la Loire as a promising medtech. A substantial achievement, especially considering the abundance and quality of technological entrepreneurship in Nantes and its region